The Story
Aragen Life Sciences has filed its draft red herring prospectus with SEBI for an initial public offering, putting one of India's largest contract research and manufacturing businesses on the listing path.
The issue comprises a fresh issue of INR800 crore and an offer for sale of up to 2,73,29,192 equity shares of face value INR10 each by selling shareholders. Fresh issue proceeds are earmarked for repayment or pre-payment of borrowings, capital expenditure on new equipment and machinery at the company's Hyderabad facilities, capital expenditure by material subsidiary Aragen Biologics at its Bengaluru facility, and general corporate purposes.
Incorporated in 2000 and formerly known as GVK Biosciences, Aragen is a fully integrated CRDMO spanning contract discovery and pre-clinical research through to contract development and manufacturing for both small molecules and biologics. The company says it is the largest CRDMO among assessed Indian peers by number of solutions offered across the drug development value chain as of 31 March 2026, and among the top three Indian CRDMOs by operating revenue in a global CRDMO market it sizes at $171 billion in fiscal 2026.
Customer concentration sits at the top of the industry. Aragen served 591 customers globally in FY26 across the United States, Europe, Japan, India and other APAC markets, and worked with 16 of the top 20 Big Pharma companies as of 31 March 2026.
On financials, revenue from operations, profit for the year, adjusted EBITDA and adjusted profit grew at CAGRs of 14.64, 26.86, 15.63 and 29.91 percent respectively, reaching INR2,178.39 crore, INR257.64 crore, INR593.77 crore and INR283.99 crore in FY26. ROCE was 18.18 percent and ROE 11.96 percent.
Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities and JM Financial are the book running lead managers.
Why It Matters
The financial profile is the argument. Profit compounding at 26.86 percent against revenue compounding at 14.64 percent means margins expanded through the period rather than volume simply scaling — the adjusted EBITDA figure of INR593.77 crore against INR2,178.39 crore of revenue works out to roughly 27 percent. For a business that is part services and part manufacturing, that is a respectable blend, and it is the number public-market investors will anchor on.
The customer roster does real work here too. Sixteen of the top 20 Big Pharma companies is a qualification statement, not just a sales figure: those relationships require audited quality systems and years of delivery history, which is precisely what a new competitor cannot buy. Spread across 591 customers, it also limits the single-client concentration risk that has hurt other listed CRDMOs.
The capital structure is where the filing is more candid than flattering. Part of the INR800 crore fresh issue goes to repaying borrowings, meaning a slice of the primary raise repairs the balance sheet rather than funding growth. And the offer for sale means a meaningful portion of the transaction is existing shareholders realising value, not money entering the company.
The demand-side caveat holds: CRDMO order books track biotech funding, and early-stage discovery work is the first line item cut when that funding tightens. Aragen's integration across the value chain cushions this, but does not remove it.
The Strategic Read
The strategic question this filing puts to the market is whether India's CRDMO sector gets rerated as infrastructure or discounted as services. The distinction matters. A services business sells hours and competes on rate. An infrastructure business owns capacity that customers design their programmes around, and switching costs rise with every molecule that passes through. Aragen's pitch — integrated across discovery, development and manufacturing, small molecule and biologics, India and the United States — is the second one. The fresh-issue use of proceeds, weighted toward equipment at Hyderabad and Bengaluru rather than acquisitions, is consistent with that.
The moat, such as it is, sits in regulatory history and relationship duration rather than in technology. Sixteen of the top 20 Big Pharma customers is not a number a new entrant assembles quickly; audit trails, quality systems and validated processes take years to build and are painful to replace mid-programme. That is a real defence. It is also a defence shared with Aragen's listed Indian peers, which is why the sector's valuation debate turns on growth rate and margin durability rather than on differentiation.
For the wider Indian startup ecosystem, the read-through is about exit paths in deep science. Aragen took Goldman Sachs money in 2021 and $100 million from Quadria Capital in January 2025 at a reported valuation near $1.4 billion. A clean public listing at scale gives Indian biotech and life-sciences founders a domestic reference point for what patient, capital-heavy R&D infrastructure is worth — something the sector has lacked relative to consumer and software.
The risks are the ordinary ones for the category: biotech funding cycles drive discovery demand, revenue is largely dollar-denominated against a rupee cost base, and pricing pressure from Chinese CRDMOs remains structural regardless of who is currently in political favour.
For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.